Urol. praxi. 2025;26(1):40-45 | DOI: 10.36290/uro.2025.023

Role of genetic testing at the deciding about the treatment of the kidney tumors

MUDr. Robert Novák, MUDr. Jana Katolická, Ph.D.
Onkologicko-chirurgické oddělení Fakultní nemocnice u sv. Anny v Brně

Renal cell carcinoma (RCC) is a histologically diverse disease, with variable and often unpredictable clinical behavior. Gene expression profiling is a promising technique for refining the diagnosis and staging of RCC, as well as for highlighting potential therapeutic targets (1).

Keywords: renal cell carcinoma, gene expression, prognosis, immunotherapy, check-points inhibitors.

Accepted: March 10, 2025; Published: March 24, 2025  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Novák R, Katolická J. Role of genetic testing at the deciding about the treatment of the kidney tumors. Urol. praxi. 2025;26(1):40-45. doi: 10.36290/uro.2025.023.
Download citation
PDF will be unlocked 24.3.2026

References

  1. Tan MH, Rogers CG, Cooper JT, et al. Gene expression profiling of renal cell carcinoma. Clin Cancer Res. 2004;10(18 Pt 2):6315S-21S. Go to original source... Go to PubMed...
  2. Vokurka S, Tesařová P, et al. Onkologie v kostce. Current Media, s.r.o., 2018; ISBN: 978-80-88129-37-0: 272 stran, 1. vydání.
  3. Fínek J, et al. Systémová léčba pokročilého a metastatického karcinomu ledviny v 21. století. Farmakon Přes, spol. s r.o., 2020; ISBN 978-80-907656-4-1; 84 stran; 1. vydání.
  4. Jurga LM, et al. Klinická a radiačná onkológia. Osveta spol. s r.o., 2010; ISBN 978-80-8063-302-8; 1658 stran, 1. vydání.
  5. Ljungberg B, Bex A, Albiges L, et al. EAU guidelines on renal cell carcinoma. https://uroweb.org/guidelines.
  6. Goswami PR, Singh G, Patel T, et al. The WHO 2022 Classification of Renal Neoplasms (5th Edition): Salient Updates.
  7. Tran HT, Liu Y, Zurita AJ, et al. Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol. 2012;13(8):827-837. Go to original source... Go to PubMed...
  8. Mukai S, Yamasaki K, Fujii M, et al. Dysregulation of Type II Trans­membrane Serine Proteases and Ligand-Dependent Activation of MET in Urological Cancers Int J Mol Sci. 2020;21(8):2663. Go to original source... Go to PubMed...
  9. www.researchgate.net/figure/HGF-MET-signaling-pathway_fig1_263354883).
  10. Shinojima T, Oya M, Takayanagi A, et al. Renal cells lacking hypoxia inducible factor (HIF)-1α expression maintain vascular endothelial growth factor expression through HIF-2α. Carcinogenesis. 2007;28(3):529-536. Go to original source... Go to PubMed...
  11. Carroll VA, Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway. Cancer Res. 2006;66(12):62646270. Go to original source... Go to PubMed...
  12. www.radcliffecardiology.com/image-gallery/31343/18793/hypoxia-inducible-factor-1α-regulation-by-proline-hydroxylation.
  13. Szendrői A, Szász AM, Kardos M, et al. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer. Oncotarget. 2016;7(27). Go to original source... Go to PubMed...
  14. Tafreshi NK, Lloyd MC, Bui MM, et al. Carbonic anhydrase IX as an imaging and therapeutic target for tumors and metastases. Subcell Biochem. 2014;75:221-54. Cureus. 2024;16(4):e58470. Go to original source... Go to PubMed...
  15. Benej M, Pastorekova S, Pastorek J. Carbonic anhydrase IX: regulation and role in cancer Subcell Biochem. 2014;75:199-219. Go to original source... Go to PubMed...
  16. Shou Y, Liu Y, Xu J, et al. TIMP1 Indicates Poor Prognosis of Renal Cell Carcinoma and Accelerates Tumorigenesis via EMT Signaling Pathway. Front Genet. 2022;25:13:648134. Go to original source... Go to PubMed...
  17. Tang Q, Chen Y, Li X, et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442. Go to original source... Go to PubMed...
  18. Kytheroutou A, Siddique A, Mauri FA, et al. PD-L1. J Clin Pathol. 2018;71:189-194. Go to original source... Go to PubMed...
  19. Van Coillie S, Wiernicki B, Xu J. Molecular and Cellular Functions of CTLA-4 Adv Exp Med Biol. 2020;1248:7-32. Go to original source... Go to PubMed...
  20. Zhang H, Liu L, Liu J, et al. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):58. Go to original source... Go to PubMed...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.